by George Ciuciureanu | Mar 10, 2025 | Health, News
Augurex has received UK Conformity Assessed marking for JOINTstat®, authorizing its use in Great Britain for rheumatoid arthritis diagnosis and management. JOINTstat® is a well-established rheumatoid arthritis blood test in North America, approved by Health Canada and...
by George Ciuciureanu | Jan 31, 2025 | Health, News
Vancouver, Canada – January 28, 2025 – The Spondylitis Association of America (SAA) invited Dr. Walter Maksymowych to join their latest episode of Spondycast, where he discusses the growing role of 14-3-3eta autoantibodies (Anti-14-3-3eta Multiplex) in the...
by Simran Chahal | Jan 27, 2025 | Health, News
Vancouver, Canada – January 27, 2025 – Delays in diagnosing axial spondyloarthritis (axSpA) have been a persistent challenge, with many patients waiting 7 to 10 years for an accurate diagnosis. These delays can lead to missed opportunities for early treatment and a...
by Simran Chahal | Nov 15, 2024 | Business, Health, News
Quest to introduce lab-developed test based on Augurex 14-3-3η (eta) biomarker to U.S. physicians later this month Vancouver, Canada – November 15, 2024 – Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced that it...
by Simran Chahal | Nov 13, 2024 | Business, Health, News
Augurex launches Anti-14-3-3eta Multiplex Analyte Specific Reagents (ASRs), supporting the development of a first-in-class diagnostic test for axial spondyloarthritis (axSpA) by New Day Diagnostics. The new laboratory developed test, which uses Anti-14-3-3eta...
by Simran Chahal | Oct 21, 2024 | Business, Health, News
Augurex Life Sciences Corp. announces the launch of the 14-3-3η test by ARUP Laboratories, enhancing the early diagnosis and management of RA.The collaboration between Augurex and ARUP Laboratories highlights a mutual dedication to improving patient outcomes and...
